KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Shares Issued (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Shares Issued for 4 consecutive years, with -$79000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Shares Issued fell 100.11% year-over-year to -$79000.0, compared with a TTM value of $74.8 million through Sep 2023, up 202.33%, and an annual FY2025 reading of $19.5 million, up 23077.38% over the prior year.
  • Shares Issued was -$79000.0 for Q4 2023 at Ginkgo Bioworks Holdings, down from $55000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $74.7 million in Q4 2022 and bottomed at -$79000.0 in Q4 2023.
  • Average Shares Issued over 4 years is $7.7 million, with a median of $27000.0 recorded in 2021.
  • The sharpest move saw Shares Issued skyrocketed 379500.0% in 2022, then tumbled 100.11% in 2023.
  • Year by year, Shares Issued stood at -$19000.0 in 2020, then soared by 763.16% to $126000.0 in 2021, then soared by 59182.54% to $74.7 million in 2022, then crashed by 100.11% to -$79000.0 in 2023.
  • Business Quant data shows Shares Issued for DNA at -$79000.0 in Q4 2023, $55000.0 in Q3 2023, and $12000.0 in Q2 2023.